510 related articles for article (PubMed ID: 30342879)
1. Pathogenesis of and New Therapies for Hepatitis D.
Koh C; Heller T; Glenn JS
Gastroenterology; 2019 Jan; 156(2):461-476.e1. PubMed ID: 30342879
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis D: A Review.
Negro F; Lok AS
JAMA; 2023 Dec; 330(24):2376-2387. PubMed ID: 37943548
[TBL] [Abstract][Full Text] [Related]
3. [Role of the hepatitis Delta virus on the pathogenesis of hepatic cirrhosis and hepatocellular carcinoma. Recent advances].
Romeo R
Recenti Prog Med; 2010 Feb; 101(2):52-6. PubMed ID: 20433000
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Delta Hepatitis: Today and in the Future - A review.
Bahcecioglu IH; Sahin A
Infect Dis (Lond); 2017 Apr; 49(4):241-250. PubMed ID: 28092214
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis D revival.
Wedemeyer H
Liver Int; 2011 Jan; 31 Suppl 1():140-4. PubMed ID: 21205152
[TBL] [Abstract][Full Text] [Related]
6. [The return of the hepatitis delta virus].
Zoutendijk R; de Jonge PJ; de Man RA
Ned Tijdschr Geneeskd; 2016; 160():D70. PubMed ID: 27405575
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology, Natural History, and Treatment of Hepatitis Delta Virus Infection in HIV/Hepatitis B Virus Coinfection.
Ferrante ND; Lo Re V
Curr HIV/AIDS Rep; 2020 Aug; 17(4):405-414. PubMed ID: 32607773
[TBL] [Abstract][Full Text] [Related]
9. Emerging concepts for the treatment of hepatitis delta.
Elazar M; Glenn JS
Curr Opin Virol; 2017 Jun; 24():55-59. PubMed ID: 28475945
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis D.
Husa P; Linhartová A; Nemecek V; Husová L
Acta Virol; 2005; 49(4):219-25. PubMed ID: 16402678
[TBL] [Abstract][Full Text] [Related]
11. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta.
Heidrich B; Yurdaydın C; Kabaçam G; Ratsch BA; Zachou K; Bremer B; Dalekos GN; Erhardt A; Tabak F; Yalcin K; Gürel S; Zeuzem S; Cornberg M; Bock CT; Manns MP; Wedemeyer H;
Hepatology; 2014 Jul; 60(1):87-97. PubMed ID: 24585488
[TBL] [Abstract][Full Text] [Related]
12. Strategies for the treatment of HBV/HDV.
Krause A; Haberkorn U; Mier W
Eur J Pharmacol; 2018 Aug; 833():379-391. PubMed ID: 29935174
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment.
Grabowski J; Yurdaydìn C; Zachou K; Buggisch P; Hofmann WP; Jaroszewicz J; Schlaphoff V; Manns MP; Cornberg M; Wedemeyer H;
Liver Int; 2011 Oct; 31(9):1395-405. PubMed ID: 21762356
[TBL] [Abstract][Full Text] [Related]
14. Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy.
Lutterkort GL; Wranke A; Hengst J; Yurdaydin C; Stift J; Bremer B; Hardtke S; Keskin O; Idilman R; Manns MP; Dienes HP; Falk C; Wedemeyer H; Heidrich B
J Viral Hepat; 2018 Nov; 25(11):1384-1394. PubMed ID: 29888837
[TBL] [Abstract][Full Text] [Related]
15. Relationship between hepatocyte proliferation and hepatitis delta virus replication in neoplastic and non-neoplastic liver tissues.
Negro F; Papotti M; Taraglio S; Rubbia-Brandt L; Giostra E; Pacchioni D; Rizzetto M; Hadengue A
J Viral Hepat; 1997 Mar; 4(2):93-8. PubMed ID: 9097264
[TBL] [Abstract][Full Text] [Related]
16. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma.
Romeo R; Del Ninno E; Rumi M; Russo A; Sangiovanni A; de Franchis R; Ronchi G; Colombo M
Gastroenterology; 2009 May; 136(5):1629-38. PubMed ID: 19208358
[TBL] [Abstract][Full Text] [Related]
17. Antiviral treatment and liver-related complications in hepatitis delta.
Wranke A; Serrano BC; Heidrich B; Kirschner J; Bremer B; Lehmann P; Hardtke S; Deterding K; Port K; Westphal M; Manns MP; Cornberg M; Wedemeyer H
Hepatology; 2017 Feb; 65(2):414-425. PubMed ID: 27770553
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of pegylated interferon monotherapy in the treatment of chronic hepatitis D virus infection: A meta-analysis.
Abdrakhman A; Ashimkhanova A; Almawi WY
Antiviral Res; 2021 Jan; 185():104995. PubMed ID: 33321155
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis D Virus and HBsAg Dynamics in the era of new Antiviral Treatments.
Shekhtman L; Duehren S; Etzion O; Cotler SJ; Dahari H
Curr Gastroenterol Rep; 2023 Dec; 25(12):401-412. PubMed ID: 37819559
[TBL] [Abstract][Full Text] [Related]
20. Combination of Novel Therapies for HDV.
Elazar M; Glenn JS
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
